BioAtla to Participate in the Citizens Life Sciences Conference
Rhea-AI Summary
BioAtla (Nasdaq: BCAB), a global clinical-stage biotechnology company, has announced its upcoming participation in the Citizens Life Sciences Conference in New York. The company, which specializes in developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, will deliver a corporate update and engage in one-on-one investor meetings.
The presentation is scheduled for Wednesday, May 7, 2025, at 10:00 a.m. ET in New York. Company management will be available for individual investor discussions during the two-day conference, which runs from May 7-8, 2025. A webcast link has been provided for those interested in following the corporate update remotely.
Positive
- Corporate update presentation at a major investor conference indicating active investor relations and market visibility
- One-on-one investor meetings suggest potential for developing strategic relationships and funding opportunities
Negative
- None.
News Market Reaction
On the day this news was published, BCAB declined 1.86%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will provide a corporate update and participate in one-on-one investor meetings at the Citizens Life Sciences Conference, to be held in New York, NY May 7-8, 2025.
Format: Corporate update and one-on-one investor meetings
Date: Wednesday, May 7, 2025
Time: 10:00 a.m. ET
Location: New York, NY
Webcast Link: Click Here
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. The Company also has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
When is BioAtla (BCAB) presenting at the Citizens Life Sciences Conference 2025?
What type of meetings will BioAtla (BCAB) hold at the Citizens Life Sciences Conference?
What is BioAtla's (BCAB) main focus in cancer treatment development?
Where can investors watch BioAtla's (BCAB) Citizens Life Sciences Conference presentation?
How long will BioAtla (BCAB) participate in the Citizens Life Sciences Conference 2025?
